Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

• Published in: The Journal of infectious diseases Vol. 220; no. 3; pp. 400 - 410
• Main Authors: Tebas, Pablo, Kraynyak, Kimberly A., Patel, Ami, Maslow, Joel N., Morrow, Matthew P., Sylvester, Albert J., Knoblock, Dawson, Gillespie, Elisabeth, Amante, Dinah, Racine, Trina, McMullan, Trevor, Jeong, Moonsup, Roberts, Christine C., Park, Young K., Boyer, Jean, Broderick, Kate E., Kobinger, Gary P., Bagarazzi, Mark, Weiner, David B., Sardesai, Niranjan Y., White, Scott M.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 02.07.2019
• Subjects: Adolescent; Adult; Antibodies, Viral - immunology; Clinical trials; Deoxyribonucleic acid; DNA; DNA vaccines; Ebola Vaccines - adverse effects; Ebola Vaccines - immunology; Ebola virus; Ebolavirus; Ebolavirus - immunology; Electroporation; Electroporation - methods; Female; Glycoproteins - immunology; Healthy Volunteers; Hemorrhagic Fever, Ebola - immunology; Humans; Immune response; Immune response (cell-mediated); Immunity, Cellular - immunology; Immunity, Humoral - immunology; Immunogenicity; Injections, Intradermal - methods; Interleukin 12; Interleukin-12 - immunology; Lymphocytes T; Male; Middle Aged; Temperature; Vaccination - methods; VACCINES; Vaccines, DNA - adverse effects; Vaccines, DNA - immunology; Young Adult; γ-Interferon; DNA vaccine; clinical trial; safety; electroporation; Ebola; immunogenicity; temperature stable

Nonlive vaccine approaches that are simple to deliver and stable at room temperature or 2-8°C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. Using an immunopotent DNA vaccine that generates protection from lethal EBOV challenge in small animals and nonhuman primates, we pe...